Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer

Journal of Clinical Oncology

Volumn 17, Issue 10, 1999, Pages 3038-3047

  Gelmon, Karen ^a   Eisenhauer, E ^a   Bryce, C ^a   Tolcher, A ^a   Mayer, L ^a   Tomlinson, E ^a   Zee, B ^a   Blackstein, M ^a   Tomiak, E ^a   Yau, J ^a   Batist, G ^a   Fisher, B ^a   Iglesias, J ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; PACLITAXEL;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; FEMALE; HAIR LOSS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; MYALGIA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032887664     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.10.3038     Document Type: Article

References (33)

1. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High dose versus low dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
2. Nabholtz JM, Gelmon KA, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:858-1867, 1996
3. Sarosy G, Kohn E, Stone DA, et al: Phase I study ot Taxol and granulocyte colony stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1165-1170, 1992
4. Seidman AD, Reichman BS, Crown JP, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995
5. Chaudhry V, Rowinsky EK, Sartorius SE, et al: Peripheral neuropathy from Taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Ann Neurol 35:304-311, 1994
6. Masurovsky EB, Peterson ER, Crain SM, et al: Microtubule arrays in Taxol treated mouse dorsal root ganglion spinal cord cultures. Brain Res 217:392-398, 1981
7. Roytta M, Raine CS: Taxol induced neuropathy: Chronic effects of local injection. J Neurocytol 15:483-496, 1986
8. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1-15, 1993 (supple 3)
9. Warner E: Neurotoxicity of cisplatin and Taxol. Int J Gynecol Cancer 5:161-169, 1995
10. Postma TJ, Vermerken JB, Liefting AJM, et al: Paclitaxel induced neuropathy. Ann Oncol 6:489-494, 1995
11. Yuhas JM, Spellman JM, Culo F: The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 3:211-216, 1980
12. Calabro Jones PM, Fahey RC, Smoluk GD, et al: Alkaline phosphatase promotes radioprotection and accumulation of WR 1065 in V79-171 cells incubated in medium containing WR 2721. Int J Radiat Biol 47:23-27, 1985
13. Yuhas JM: Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 40:1519-1524, 1980
14. Wang LM, Wang QW, Fernandes DJ, et al: Amifostine protects MRC-5 human lung fibroblasts from Taxol toxicity without reducing its cytotoxic effect against human non-small cell lung cancer cells. Proc Am Assoc Cancer Res 36:288a, 1995 (abstr 1712)
15. Taylor CW, Wang LM, List AF, et al: Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur J Cancer 33:1693-1698, 1997
16. Paine GD, Taylor CW, Lopez MH, et al: Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immunodeficient mouse: Preliminary results. Semin Oncol 23:35-39, 1996 (suppl 8)
17. Treskes M, Boven E, Holwerda U, et al: Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR 2721 in the mouse. Cancer Res 52:2257-2260, 1992
18. Treskes M, Boven E, Loosdrecht AA, et al: Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin treated mice. Eur J Cancer 30:183-187, 1994
19. Mollman JE: Cisplatin neuropathy: Risk factors, prognosis and protection by WR 2721. Cancer 61:2192-2195, 1988
20. Kemp G, Rose P, Lurain J, et al: Amifostine pretreatment for protection against cyclophosphamide induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112, 1996
21. DiPaola R, Rodriguez R, Recio A, et al: A phase I study of paclitaxel and amifostine in patients with advanced malignancies. Proc Am Soc Clin Oncol 15:488, 1996 (abstr)
22. Harris JW, Rahman A, Bok-Ryang K, et al: Metabolism of Taxol by human hepatic microsomes and liver slices: Participation of cytochrome p450 3A4 and an unknown p450 enzyme. Cancer Res 54:4026-4035, 1994
23. 2 test. J R Stat Soc Suppl 1:217-235, 1934
24. Fleiss J: Statistical Methods for Rates and Proportions (ed 2). New York, NY, Wiley, 1985
25. Henderson IC, Berry D, Demetri G, et al: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 390A)
26. Shaw LM, Turrisi AT, Glover DJ, et al: Human pharmacokinetics of WR-2721. Ini J Radiat Oncol Biol Phys 12:1501-1504, 1986
27. US Bioscience Pharmacokinetics of double dose amifostine (WR 2721) Ethyol) with corresponding measurements of WR 1065 in plasma and bone marrow cells. ETH PK 4 1994. Palo Alto, CA, U.S. Bioscience, 1994
28. Schüller J, Czejka M, Pietrzak C, et al: Influence of the cytoprotective agent amifostine (AMI) on pharmacokinetics (PK) of paclitaxel (PAC) and Taxotere® (TXT). Proc Am Soc Clin Oncol Abst 16:224a, 1997 (abstr 785)
29. Winer E, Berry D, Duggan D, et al: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: Results from CALGB 9342. Proc Am Soc Clin Oncol 17:101 a, 1998 (abstr 388)
30. Mitchell RB: Amifostine to ameliorate the neurotoxicity of carboplatin/paclitaxel for advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 17:495a, 1998 (abstr 1906)
31. Carlo-Stella C, Dodero A, Regazzi E, et al: Amifostine enhances chemotherapy-elicited peripheral blood progenitor cell mobilization. Proc Am Soc Clin Oncol 17:78a, 1998 (abstr 301)
32. Reece D, Glenn C, Hale G, et al: Acute effects of multiple doses of Ethyol® (amifostine [AF]) plus high dose paclitaxel (P), cyclophosphamide (CY), cisplatin (cDDP) and autologous stem cell transplantation (ASCT) in patients (PTS) with metastatic breast cancer. Proc Am Soc Clin Oncol 17:94a, 1998 (abstr 364)
33. De Lena M, Catino A, Lorusso V, et al: Amifostine (AMF) protects against doxorubicin (D) toxicity with preservation of therapeutic activity in advanced breast cancer (ABC) patients. Proc Am Soc Clin Oncol 17:137a, 1998 (abstr 521)